- Previous Close
2.9600 - Open
2.9800 - Bid 2.9800 x --
- Ask 2.9800 x --
- Day's Range
2.9200 - 2.9800 - 52 Week Range
2.7700 - 4.4800 - Volume
11,458 - Avg. Volume
38,627 - Market Cap (intraday)
225.488M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.20
Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through Diagnosis, Oncology, and Preventive Medicine segments. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; online medical imaging in the fields of radiology and cardiology; oncology treatment services, such as chemotherapy, immunotherapy, radiotherapy, and brachytherapy; second opinion and genetic counselling; and diagnostic reports and genetic tests. It also provides telemedicine services, such as teleradiology, telecardiology, teleoncology, teledermatology, teleophthalmology, and teleconsultations; prevention plans for companies, which includes training plans on occupational risk prevention; Smart Data, a technological database for healthcare; and research and development services. The company was formerly known as Althia Health, S.L. and changed its name to Atrys Health, S.A. in May 2016. Atrys Health, S.A. was incorporated in 2007 and is headquartered in Madrid, Spain.
www.atryshealth.comRecent News: ATRY.MC
View MorePerformance Overview: ATRY.MC
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is IBEX 35... (^IBEX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATRY.MC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATRY.MC
View MoreValuation Measures
Market Cap
224.73M
Enterprise Value
361.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.05
Price/Book (mrq)
0.89
Enterprise Value/Revenue
1.70
Enterprise Value/EBITDA
18.96
Financial Highlights
Profitability and Income Statement
Profit Margin
-14.12%
Return on Assets (ttm)
0.80%
Return on Equity (ttm)
-11.73%
Revenue (ttm)
224.98M
Net Income Avi to Common (ttm)
-31.61M
Diluted EPS (ttm)
-0.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
20.36M
Total Debt/Equity (mrq)
77.98%
Levered Free Cash Flow (ttm)
36.02M